871498-18-9 Usage
Chemical compound
2-amino-3-(6-fluoro-1H-indol-3-yl)-propionic acid methyl ester
Chemical classification
Methyl ester derivative
Derivative of
2-amino-3-(6-fluoro-1H-indol-3-yl)-propionic acid
Synthetic derivative of the neurotransmitter glutamate
Acts as an agonist at the glutamate receptors
Specific receptors targeted
Group I metabotropic glutamate receptors
Studied for potential use in the treatment of neurological disorders
Neurological disorders studied for
Alzheimer's disease, Parkinson's disease, schizophrenia
Investigated for potential role in modulating synaptic plasticity
Research focus on development of new therapeutic strategies for cognitive impairment and memory deficits
More research needed for full understanding of pharmacological properties and clinical applications
Check Digit Verification of cas no
The CAS Registry Mumber 871498-18-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,4,9 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 871498-18:
(8*8)+(7*7)+(6*1)+(5*4)+(4*9)+(3*8)+(2*1)+(1*8)=209
209 % 10 = 9
So 871498-18-9 is a valid CAS Registry Number.
871498-18-9Relevant articles and documents
MITHRAMYCIN DERIVATIVES HAVING INCREASED SELECTIVITY AND ANTI-CANCER ACTIVITY
-
Paragraph 0097, (2019/04/05)
Mithramycin side chain carboxylic acid (MTM-SA) derivative are provided, which include a substituted amino acid derivative, a substituted amino acid dipeptide derivative, or an unsubstituted dipeptide derivative. The MTM-SA derivatives are useful for treatment of cancer or neuro-diseases associated with an aberrant erythroblast transformation-specific transcription factor. Unique MTM-SA derivatives have increased selectively toward ETS transcription factor.
N-benzoyl amino acids as LFA-1/ICAM inhibitors 1: Amino acid structure-activity relationship
Burdick, Daniel J.,Paris, Ken,Weese, Kenneth,Stanley, Mark,Beresini, Maureen,Clark, Kevin,McDowell, Robert S.,Marsters Jr., James C.,Gadek, Thomas R.
, p. 1015 - 1018 (2007/10/03)
The association of ICAM-1 with LFA-1 plays a critical role in several autoimmune diseases. N-2-Bromobenzoyl L-tryptophan, compound 1, was identified as an inhibitor to the formation of the LFA-1/ICAM complex. The SAR of the amino acid indicates that the carboxylic acid is required for inhibition and that L-histidine is the most favored amino acid.
